ArticleInternational journal of clinical and experimental pathology2017
Angiopoietin-1 alleviates LPS-induced inflammatory injury by up-regulation of miR-126 in pancreas cell line HPDE6-C7.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- MiR-126-Loaded Immunoliposomes against Vascular Endothelial Inflammation In Vitro and Vivo Evaluation.Pharmaceutics · 2023Article
- The Role of MicroRNAs in Pancreatitis Development and Progression.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute pancreatitis is an inflammatory disorder of the pancreas, leading to multiple organ dysfunction syndrome in severe cases. Angiopoietin-1 (Ang-1), a Tie-2 receptor agonist, and microRNA-126 (miR-126) have been reported to be involved in angiogenesis and anti-inflammatory functions. In the present study, we explored the effects of Ang-1 and miR-126 on lipopolysaccharide (LPS)-induced inflammatory injury in pancreatic cells, HPDE6-C7.
methodsThe immortalized human pancreatic duct epithelial cell line, HPDE6-C7, was treated with LPS (10 µg/mL) to induce cell injury. Ang-1 was used at 300 ng/mL concentration. Cell viability was measured using CCK-8 assay and apoptosis was assessed using flow cytometry. Quantitative real time polymerase chain reaction (RT-PCR) was used to measure the mRNA expressions of different proteins. Enzyme linked immunosorbent assay (ELISA) was used to measure the concentrations of the pro-inflammatory cytokines. Luciferase activity assay was done to identify the target of miR-126. Western blot was used to measure the expressions of different proteins.
resultsAng-1 promoted LPS-suppressed cell viability and inhibited LPS-induced cell apoptosis, pro-inflammatory cytokine (TNF-α, IL-1β, IL-6, and IL-8) production, and activation of NF-κB and JNK pathways in HPDE6-C7 cells. Furthermore, Ang-1 promoted the expression of miR-126, which in turn protected PDE6-C7 cells against LPS-induced injury. PDCD4 was identified as a direct target of miR-126 and was negatively regulated by miR-126. Mechanistic study revealed that overexpression of PDCD4 reversed miR-126-mediated inhibition of LPS-induced activation of NF-κB and JNK pathways.
conclusionAng-1 alleviates LPS-induced inflammatory injury by up-regulation of miR-126 and down-regulation of PDCD4 in pancreatic cell line HPDE6-C7.
Indexed as
Identifiers
31966500PMC6966023W3008186745What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.